Clinical trial · Observational
Organ Motion and Early Tumor Response Measurement
Organ Motion and Early Tumor Response Measurement During Chemotherapy for Esophageal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To quantify motion based variation of the target volume of the primary tumor over the course of chemoradiotherapy in esophageal cancer patients, and to use this information to calculate appropriate PTV (planning target volume) margins according to the margins recipe for patients receiving trimodality (neoadjuvant chemoradiation and surgery) or definitive chemoradiation in order to personalize radiation treatment, resulting in either better target coverage or a reduction in normal tissue radiation exposure.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemoradiation | — | UNRESOLVED | — |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fiducial markers | Other | — | UNRESOLVED |
| Fiducial markers, Pet and MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- neoadjuvant or definitive chemoradiation
- description
- Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
- interventionNames
- Other: Fiducial markers
- Other: Fiducial markers, Pet and MRI
Primary outcomes (1)
- measure
- To quantify motion of the esophageal tumor over the course of chemoradiation
- timeFrame
- 6 weeks
- description
- The outcome measures will be assessed by tracking the motion of the fiducial markers at the daily 4D CBCT (four dimensional cone beam CT scan). (primary outcome) By observing the motion of the fiducial, the exact setup error, breathing motion amplitudes, intra- and inter-fraction motion can be assessed.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologic evidence of invasive adenocarcinoma or squamous cell cancer of the esophagus 2. Patient eligible for trimodality treatment (chemoradiotherapy and surgery) or definitive chemoradiotherapy 3. T3N0M0 or T1-4N1-3M0. Patients with M1 disease solely on the basis of supraclavicular metastasis and not a junction tumor as primary are eligible. (AJCC 7th edition,). 4. WHO performance status ≤2 (WHO scale) 5. Clinically operable for R0 resection in the opinion of an experienced upper gastrointestinal or thoracic surgeon for patients planned for trimodality 6. Tumor localization at least 2cm from the upper esophageal sphincter and invading no more than 5cm into gastric cardia 7. Age ≥ 18 years 8. Written informed consent before endoscopy or EUS Exclusion criteria: 1. Prior treatment with thoracic surgery or thoracic radiotherapy 2. Pregnancy 3. Severe cardiopulmonary restriction
References
Publications (1)
- DERIVEDVollenbrock SE, Voncken FEM, Lambregts DMJ, Maas M, Donswijk ML, Vegt E, Ter Beek LC, van Dieren JM, van Sandick JW, Aleman BMP, Beets-Tan RGH, Bartels-Rutten A. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):176-185. doi: 10.1007/s00259-020-04917-5. Epub 2020 Jun 22. PMID 32572560